Tonix Pharmaceuticals reported net product revenue of approximately $13.5 million in Q2 2026, up from $2 million in Q2 2025. TONMYA net sales reached approximately $11 million, representing 197% quarter-over-quarter growth. Prescriptions for TONMYA totalled 12,592 in Q2, a 100% quarter-over-quarter increase. Refills increased 207% during the same period. Market access coverage expanded to 136 million covered lives, with agreements expected to reach 145 million lives by January 2027. The company plans to expand its sales force to 150 representatives by September 2026. Cash and cash equivalents stood at approximately $176.2 million as of 30 June 2026, down from $207.6 million at year-end 2025. Research and development expenses rose to approximately $19.4 million in Q2 2026, whilst selling, general, and administrative expenses increased to approximately $36 million.

InvestorNewsBreaks - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presents real-world fibromyalgia burden data at ISPOR 2026. Tonix Pharmaceuticals (NASDAQ: TNXP) presented real-world claims analysis data at ISPOR 2026 highlighting the significant clinical and economic burden of fibromyalgia in U.S. adults, with findings showing high rates of comorbidities, extensive healthcare resource utilization and widespread reliance on multimodal treatment approaches. The retrospective analysis of more than 261,000 adult fibromyalgia patients found that more than 93% had at least one fibromyalgia-related comorbidity, while insured patients incurred substantial annual healthcare costs driven primarily by inpatient services, underscoring the unmet need for more effective long-term treatment options as Tonix advances its planned commercial launch of TONMYA. Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA(TM)(cyclobenzaprine HCl sublingual tablets 2.8mg), the Company's recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R). Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP About InvestorWire InvestorWire ("IW") is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer InvestorWire is powered by IBN

Tonix Pharmaceuticals has secured commercial payer coverage for Tonmya through a group purchasing organisation agreement, providing access to approximately 35 million US commercial lives, representing roughly 20% of the commercial market. The drug is now covered under Medicaid in 38 states, representing approximately 55 million covered lives. Since Tonmya's November 2025 approval, the commercial launch has shown encouraging metrics. In the first quarter of 2026, 2,145 healthcare providers prescribed Tonmya to 3,588 unique patients, with approximately 5,400 prescriptions filled. By May 2026, over 2,700 providers had prescribed the drug to 5,600 patients, with more than 11,000 prescriptions filled. First quarter net revenue of $3.7 million exceeded analyst estimates of $2 million, though the company maintains a conservative outlook for 2026.